Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill
Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy…
Obesity not a ‘zero-sum game’ as patients crave optionality, Novo CEO says: Reuters
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk…
Novo Nordisk CEO Says Obesity Drug Market Won’t Be Winner-Take-All — BigGo Finance
Novo Nordisk (NVO) CEO Mike Doustdar pushed back Wednesday against the prevailing investor narrative that the booming obesity…
Lilly’s Foundayo Pill Lands First European Approval, Challenging Novo’s Wegovy in UK — BigGo Finance
Eli Lilly and Co. (LLY) has secured its first international approval for the oral weight-loss drug Foundayo, winning…
NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
Oral Wegovy is now cleared in all EU member states. The European Commission also approved a convenient single-dose…
In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s
The launch of weight-loss pills is the hottest battle in pharma. So far, Eli Lilly is losing to…
Novo Nordisk CEO Dustar: Obesity Has Eclipsed Diabetes at ADA as Lilly’s Retatrutide Hits 28.3% Weight Loss — BigGo Finance
When the chief executive of the world’s most valuable obesity-drug company admits he’s surprised that a diabetes conference…
‘Familiarity’ with oral Wegovy has triggered its quick uptake
What’s been Novo Nordisk’s secret weapon to turn the tables on Eli Lilly and win the current market…
The Oral GLP-1 Tracker: Week 1 of Lilly’s Foundayo launch
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started…
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in…
Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth | Company News
Obesity patients at Juan Manuel Esparza Luna’s clinic in Chihuahua, Mexico, have options to slim down, with…
Novo Nordisk Q1 2026 Earnings: Revenue, Profit Beat; Full-Year Forecast Narrowed | Reuters – News and Statistics
May 7, 2026 Novo Nordisk, the manufacturer of the weight-loss drug Wegovy, reported first-quarter revenue and adjusted operating…